Chronic D2/3 agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns

• Published in: The European journal of neuroscience 2017-01, Vol.45 (1), p.159-166
• Main Authors: Tremblay, Melanie, Silveira, Mason M., Kaur, Sukhbir, Hosking, Jay G., Adams, Wendy K., Baunez, Christelle, Winstanley, Catharine A., Dalley, Jeffrey
• Format: Article
• Language: English
• Subjects: 6-Hydroxydopamine; Animals; Dopamine; dopamine agonist; Dopamine D2 receptors; Gambling; GSK3β; Impulsive behavior; impulsivity; Movement disorders; Neostriatum; Neurodegenerative diseases; Parkinson's disease; Preferences; Rats; Reinforcement; Rodents; Side effects; Uncertainty
• ISSN: 0953-816X; 1460-9568
• DOI: 10.1111/ejn.13332

D2/3 receptor agonists are effective treatments for Parkinson's disease (PD), but can precipitate impulse control disorders (ICDs) including gambling disorder (GD). The neurobiological mechanisms underlying this devastating side‐effect of dopamine agonist replacement therapy (DRT), and any dependence on the dopamine depletion caused by PD, are unclear. It is also unclear whether previous biases towards risk or uncertainty are a risk factor for developing these ICDs. We investigated whether chronic D2/3 agonist administration (5 mg/kg/day ropinirole for 28 days) altered performance of a rat model of gambling‐like behaviour, the rodent betting task (rBT), and examined if baseline behaviour predicted this behavioural change. The rBT captures individual differences in subjective preference for uncertain outcomes: animals choose between guaranteed or probabilistic reinforcement of equal expected value. Chronic ropinirole dramatically increased selection of the uncertain option in two‐thirds of animals, regardless of baseline preferences. The effect on choice in the rBT was replicated in a dorsolateral striatal 6‐hydroxydopamine (6‐OHDA) rat model of early PD. These studies are the first to look at individual differences in response to chronic, rather than pulsatile, dosing of DRT in a rodent model of gambling behaviour. These findings suggest that DRT‐induced PG may stem from increases in subjective valuation of uncertainty. Such symptoms likely arise because of changes in dopaminergic striatal signalling caused by DRT rather than from an interaction between pre‐morbid behaviours or PD itself. Here, we report that chronic administration of the D2/3 receptor agonist ropinirole increased preference for uncertainty on a rat model of gambling‐like behaviour, the rodent betting task (rBT), in both healthy rats and in a 6‐OHDA lesion model of early‐stage Parkinson's disease (PD). This suggests that D2/3 agonist‐induced impulse control disorders (ICDs) are caused by drug treatment independent from pre‐morbid behaviours or PD itself.